Literature DB >> 11120423

Zuclopenthixol acetate in psychiatric emergencies: looking for evidence from clinical trials.

E Coutinho1, M Fenton, C Adams, C Campbell.   

Abstract

BACKGROUND: Case series and reviews have suggested the effectiveness of zuclopenthixol acetate in the acute management of disturbed behaviour caused by serious mental illnesses. This review investigates the trial-based evidence for these suggestions.
METHODS: All randomized clinical trials comparing zuclopenthixol acetate to other 'standard' treatments for the acute management of those with serious mental illnesses were identified and, if possible, their results summated.
RESULTS: Six trials were identified. All had methodological problems and one did not meet the minimal methodological inclusion criteria. The summary data do not demonstrate that zuclopenthixol acetate is better than 'standard care' for altering behaviour, decreasing the need for supplementary medication, avoiding side-effects, or postponing early discharge against medical advice. One trial, however, presented data that suggested an earlier, more intense level of sedation.
CONCLUSIONS: Recommendations of reviews and open studies for the use of zuclopenthixol acetate in preference to 'standard' treatments in the psychiatric emergency are not supported by evidence from randomized controlled trials.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120423     DOI: 10.1016/s0920-9964(99)00226-1

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  4 in total

1.  Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine.

Authors: 
Journal:  BMJ       Date:  2003-09-27

2.  Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.

Authors:  S J C Davies; S Eayrs; P Pratt; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

Review 3.  Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.

Authors:  Kaushadh Jayakody; Roger Carl Gibson; Ajit Kumar; Shalmini Gunadasa
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

4.  TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243].

Authors:  Gisele Huf; Evandro S F Coutinho; Clive E Adams
Journal:  BMC Psychiatry       Date:  2002-10-16       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.